vs

Side-by-side financial comparison of Charles River Laboratories (CRL) and Leonardo DRS, Inc. (DRS). Click either name above to swap in a different company.

Leonardo DRS, Inc. is the larger business by last-quarter revenue ($1.1B vs $995.8M, roughly 1.1× Charles River Laboratories). Leonardo DRS, Inc. runs the higher net margin — 9.6% vs -1.5%, a 11.1% gap on every dollar of revenue. On growth, Leonardo DRS, Inc. posted the faster year-over-year revenue change (8.1% vs 1.2%). Over the past eight quarters, Leonardo DRS, Inc.'s revenue compounded faster (24.1% CAGR vs -1.5%).

Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices.

Leonardo DRS, Inc. is a United States–based defense contractor. Originally founded as DRS Technologies, Inc. and traded on the NYSE, it was acquired by Leonardo’s predecessor Finmeccanica in 2008. Leonardo DRS provides advanced defense technologies and systems primarily to the U.S. military.

CRL vs DRS — Head-to-Head

Bigger by revenue
DRS
DRS
1.1× larger
DRS
$1.1B
$995.8M
CRL
Growing faster (revenue YoY)
DRS
DRS
+6.9% gap
DRS
8.1%
1.2%
CRL
Higher net margin
DRS
DRS
11.1% more per $
DRS
9.6%
-1.5%
CRL
Faster 2-yr revenue CAGR
DRS
DRS
Annualised
DRS
24.1%
-1.5%
CRL

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CRL
CRL
DRS
DRS
Revenue
$995.8M
$1.1B
Net Profit
$-14.8M
$102.0M
Gross Margin
25.4%
Operating Margin
12.0%
11.9%
Net Margin
-1.5%
9.6%
Revenue YoY
1.2%
8.1%
Net Profit YoY
-157.2%
14.6%
EPS (diluted)
$-0.30
$0.38

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CRL
CRL
DRS
DRS
Q1 26
$995.8M
Q4 25
$994.2M
$1.1B
Q3 25
$1.0B
$960.0M
Q2 25
$1.0B
$829.0M
Q1 25
$984.2M
$799.0M
Q4 24
$1.0B
$981.0M
Q3 24
$1.0B
$812.0M
Q2 24
$1.0B
$753.0M
Net Profit
CRL
CRL
DRS
DRS
Q1 26
$-14.8M
Q4 25
$-276.6M
$102.0M
Q3 25
$54.4M
$72.0M
Q2 25
$52.3M
$54.0M
Q1 25
$25.5M
$50.0M
Q4 24
$-214.5M
$89.0M
Q3 24
$69.7M
$57.0M
Q2 24
$94.1M
$38.0M
Gross Margin
CRL
CRL
DRS
DRS
Q1 26
Q4 25
25.4%
Q3 25
23.1%
Q2 25
23.8%
Q1 25
22.7%
Q4 24
24.0%
Q3 24
34.6%
22.0%
Q2 24
34.5%
22.4%
Operating Margin
CRL
CRL
DRS
DRS
Q1 26
12.0%
Q4 25
-28.5%
11.9%
Q3 25
13.3%
9.7%
Q2 25
9.7%
8.4%
Q1 25
7.6%
7.4%
Q4 24
-16.7%
12.2%
Q3 24
11.6%
9.2%
Q2 24
14.8%
7.3%
Net Margin
CRL
CRL
DRS
DRS
Q1 26
-1.5%
Q4 25
-27.8%
9.6%
Q3 25
5.4%
7.5%
Q2 25
5.1%
6.5%
Q1 25
2.6%
6.3%
Q4 24
-21.4%
9.1%
Q3 24
6.9%
7.0%
Q2 24
9.2%
5.0%
EPS (diluted)
CRL
CRL
DRS
DRS
Q1 26
$-0.30
Q4 25
$-5.57
$0.38
Q3 25
$1.10
$0.26
Q2 25
$1.06
$0.20
Q1 25
$0.50
$0.19
Q4 24
$-4.17
$0.34
Q3 24
$1.33
$0.21
Q2 24
$1.74
$0.14

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CRL
CRL
DRS
DRS
Cash + ST InvestmentsLiquidity on hand
$191.8M
$647.0M
Total DebtLower is stronger
$321.0M
Stockholders' EquityBook value
$2.9B
$2.7B
Total Assets
$7.7B
$4.5B
Debt / EquityLower = less leverage
0.12×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CRL
CRL
DRS
DRS
Q1 26
$191.8M
Q4 25
$213.8M
$647.0M
Q3 25
$207.1M
$309.0M
Q2 25
$182.8M
$278.0M
Q1 25
$229.4M
$380.0M
Q4 24
$194.6M
$598.0M
Q3 24
$210.2M
$198.0M
Q2 24
$179.2M
$149.0M
Total Debt
CRL
CRL
DRS
DRS
Q1 26
Q4 25
$2.1B
$321.0M
Q3 25
$2.2B
$326.0M
Q2 25
$2.3B
$331.0M
Q1 25
$2.5B
$335.0M
Q4 24
$2.2B
$340.0M
Q3 24
$2.3B
$345.0M
Q2 24
$2.4B
$351.0M
Stockholders' Equity
CRL
CRL
DRS
DRS
Q1 26
$2.9B
Q4 25
$3.2B
$2.7B
Q3 25
$3.4B
$2.6B
Q2 25
$3.4B
$2.6B
Q1 25
$3.2B
$2.6B
Q4 24
$3.5B
$2.6B
Q3 24
$3.8B
$2.5B
Q2 24
$3.7B
$2.4B
Total Assets
CRL
CRL
DRS
DRS
Q1 26
$7.7B
Q4 25
$7.1B
$4.5B
Q3 25
$7.5B
$4.2B
Q2 25
$7.6B
$4.1B
Q1 25
$7.6B
$4.1B
Q4 24
$7.5B
$4.2B
Q3 24
$8.0B
$3.9B
Q2 24
$7.9B
$3.8B
Debt / Equity
CRL
CRL
DRS
DRS
Q1 26
Q4 25
0.68×
0.12×
Q3 25
0.64×
0.12×
Q2 25
0.70×
0.13×
Q1 25
0.79×
0.13×
Q4 24
0.65×
0.13×
Q3 24
0.62×
0.14×
Q2 24
0.65×
0.15×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CRL
CRL
DRS
DRS
Operating Cash FlowLast quarter
$41.1M
$425.0M
Free Cash FlowOCF − Capex
$376.0M
FCF MarginFCF / Revenue
35.5%
Capex IntensityCapex / Revenue
5.6%
4.6%
Cash ConversionOCF / Net Profit
4.17×
TTM Free Cash FlowTrailing 4 quarters
$227.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CRL
CRL
DRS
DRS
Q1 26
$41.1M
Q4 25
$147.5M
$425.0M
Q3 25
$213.8M
$107.0M
Q2 25
$204.6M
$-28.0M
Q1 25
$171.7M
$-138.0M
Q4 24
$159.4M
$443.0M
Q3 24
$251.8M
$59.0M
Q2 24
$193.5M
$34.0M
Free Cash Flow
CRL
CRL
DRS
DRS
Q1 26
Q4 25
$58.6M
$376.0M
Q3 25
$178.2M
$77.0M
Q2 25
$169.3M
$-56.0M
Q1 25
$112.4M
$-170.0M
Q4 24
$83.7M
$414.0M
Q3 24
$213.1M
$47.0M
Q2 24
$154.0M
$0
FCF Margin
CRL
CRL
DRS
DRS
Q1 26
Q4 25
5.9%
35.5%
Q3 25
17.7%
8.0%
Q2 25
16.4%
-6.8%
Q1 25
11.4%
-21.3%
Q4 24
8.4%
42.2%
Q3 24
21.1%
5.8%
Q2 24
15.0%
0.0%
Capex Intensity
CRL
CRL
DRS
DRS
Q1 26
5.6%
Q4 25
8.9%
4.6%
Q3 25
3.5%
3.1%
Q2 25
3.4%
3.4%
Q1 25
6.0%
4.0%
Q4 24
7.5%
3.0%
Q3 24
3.8%
1.5%
Q2 24
3.8%
4.5%
Cash Conversion
CRL
CRL
DRS
DRS
Q1 26
Q4 25
4.17×
Q3 25
3.93×
1.49×
Q2 25
3.91×
-0.52×
Q1 25
6.74×
-2.76×
Q4 24
4.98×
Q3 24
3.61×
1.04×
Q2 24
2.06×
0.89×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CRL
CRL

Service revenue$798.2M80%
Product revenue$197.7M20%

DRS
DRS

Segment breakdown not available.

Related Comparisons